c‐Kit Mutation and Localization Status as Response Predictors in Mast Cell Tumors in Dogs Treated with Prednisone and Toceranib or Vinblastine

BACKGROUND: KIT inhibitors, such as toceranib (TOC), and vinblastine (VBL) have not been prospectively compared in the treatment of macroscopic mast cell tumors (MCTs). Also, it is unknown whether VBL or TOC is superior for treating MCT without c‐kit mutations. HYPOTHESIS/OBJECTIVES: To determine th...

Descripción completa

Detalles Bibliográficos
Autores principales: Weishaar, K.M., Ehrhart, E.J., Avery, A.C., Charles, J.B., Elmslie, R.E., Vail, D.M., London, C.A., Clifford, C.A., Eickhoff, J.C., Thamm, D.H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
SMALL ANIMAL
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5787208/
https://www.ncbi.nlm.nih.gov/pubmed/29194765
http://dx.doi.org/10.1111/jvim.14889

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5787208/
https://www.ncbi.nlm.nih.gov/pubmed/29194765
http://dx.doi.org/10.1111/jvim.14889

Ejemplares similares